Payment overview · 2025
General Payments
$658.40
41 reported records · 12 companies
Healthcare provider profile · identity verified
Ryan Flamion, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOLLAND, IN · NPI 1649319054
Verified facts
What the public records show
CMS Open Payments records show Ryan Flamion, MD received $658.40 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 54.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $356.97 | 54.2% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.81 | 7.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.13 | 5.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.44 | 5.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.74 | 5.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.47 | 4.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.66 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.38 | 2.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.94 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.80 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.20 | 2.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.86 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $658.40 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $197.17 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.80 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $93.74 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 600 | 134 |
| Omeprazole | Omeprazole | 368 | 94 |
| Lisinopril | Lisinopril | 332 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 67 |
| Metformin Hcl | Metformin Hcl | 297 | 67 |
| Furosemide | Furosemide | 296 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 53 |
| Eliquis | Apixaban | 267 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 52 |
| Gabapentin | Gabapentin | 189 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 44 |
| Losartan Potassium | Losartan Potassium | 173 | 44 |
| Prednisone | Prednisone | 164 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 40 |
| Xarelto | Rivaroxaban | 155 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 147 | 35 |
| Potassium Chloride | Potassium Chloride | 146 | 37 |
| Carvedilol | Carvedilol | 145 | 40 |
| Sertraline Hcl | Sertraline Hcl | 143 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 31 |
| Jardiance | Empagliflozin | 139 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 31 |
| Donepezil Hcl | Donepezil Hcl | 134 | 21 |
| Famotidine | Famotidine | 133 | 24 |
| Meloxicam | Meloxicam | 130 | 26 |
| Farxiga | Dapagliflozin Propanediol | 128 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 32 |
| Ozempic | Semaglutide | 117 | 18 |
| Allopurinol | Allopurinol | 109 | 25 |
| Trazodone Hcl | Trazodone Hcl | 108 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 14 |
| Alprazolam | Alprazolam | 92 | 17 |
| Lorazepam | Lorazepam | 86 | 18 |
| Bupropion Xl | Bupropion Hcl | 85 | 13 |
| Buspirone Hcl | Buspirone Hcl | 82 | 16 |
| Glipizide | Glipizide | 81 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Clonazepam | Clonazepam | 79 | 14 |
| Simvastatin | Simvastatin | 76 | 17 |
| Spironolactone | Spironolactone | 72 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 12 |
| Finasteride | Finasteride | 69 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 24 |
| Mirtazapine | Mirtazapine | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 67 | 14 |
| Atenolol | Atenolol | 65 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 15 |
| Verapamil Er | Verapamil Hcl | 60 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | suppressed |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Glimepiride | Glimepiride | 54 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 12 |
| Cephalexin | Cephalexin | 48 | 33 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 38 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 17 |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | 11 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Hydrocortisone | Hydrocortisone | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 13 |
| Veltassa | Patiromer Calcium Sorbitex | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 19 |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Azithromycin | Azithromycin | 33 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Diazepam | Diazepam | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Leflunomide | Leflunomide | 21 | suppressed |
| Renvela | Sevelamer Carbonate | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sirolimus | Sirolimus | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Tacrolimus | Tacrolimus | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $658.40 · 41 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error